Recent Updates
Recently added Catalysts
ALVO Positive Sentiment

Alvotech to present at upcoming investor conferences in June

Key Takeaway: Alvotech has announced its participation in several investor conferences in June 2026, including the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. Key executives, Robert Wessman and Dr. Balaji V. Prasad, will engage in fireside chats to discuss the company's developments. Live webcasts will be accessible to the public, with recordings available post-event.
Price reaction · baseline $3.22 (2026-06-01 close) · hit after-hours · 3 other ALVO headline(s) in the window, move may be shared
day 0 close
-6.8%
day 1
-2.5%
day 3 · peak
+9.9%

Conference Participation Details

Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in multiple prestigious investor conferences.
  • Opportunity for live engagement with investors and the public.
  • Showcases Alvotech's commitment to transparency and communication.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+128%
120-day peak, hindsight
Typical move
13.8%
average across 7 past catalysts
Lead asset
Stelara
Phase 3 · Psoriasis

Full Press Release Details

REYKJAVIK, Iceland, June 02, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Robert Wessman, Alvotech's Founder and Executive Chairman, and Dr. Balaji V. Prasad, Chief Strategy Officer, will participate in the upcoming investor conferences in June as follows:
• Jefferies Global Healthcare Conference in New York –fireside chat on Thursday, June 4, 2026 at 9:20 am ET
• Goldman Sachs 47thAnnual Global Healthcare Conference in Miami –fireside chat Monday, June 8, 2026 at 8:40 am ET
• UBS Virtual Generics and Biosimilars Day– fireside chat on Wednesday, June 10, 2026 at 10:30 am ET
The live audio webcasts will be available to investors and the general public and can be accessed in the Investors Section of Alvotech’s website underNews and Events – Events and Presentations. After the event, a recording will also be available for up to 90 days.

MediaBenedikt StefanssonSarah MacLeodalvotech.media@alvotech.com

InvestorsDr. Balaji V PrasadBenedikt Stefanssonalvotech.ir@alvotech.com

About AlvotechAlvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visithttps://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
For more information, please visit ourinvestor portal, and ourwebsiteor follow us on social media onLinkedIn,Facebook,InstagramandYouTube.

Frequently Asked Questions

When will Alvotech participate in investor conferences?

Alvotech will participate in investor conferences on June 4, 8, and 10, 2026.

Who will represent Alvotech at the conferences?

Robert Wessman and Dr. Balaji V. Prasad will represent Alvotech.

How can the public access the conference webcasts?

The live audio webcasts can be accessed in the Investors Section of Alvotech's website.

What is Alvotech's focus as a biotechnology company?

Alvotech specializes in the development and manufacture of biosimilar medicines.

Last updated: Jun 2, 2026